748 related articles for article (PubMed ID: 18473850)
1. Advanced glycation end products and insulin resistance.
Unoki H; Yamagishi S
Curr Pharm Des; 2008; 14(10):987-9. PubMed ID: 18473850
[TBL] [Abstract][Full Text] [Related]
2. Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes.
Yamagishi S; Matsui T; Nakamura K
Curr Drug Targets; 2007 Oct; 8(10):1138-43. PubMed ID: 17979674
[TBL] [Abstract][Full Text] [Related]
3. Advanced glycation end products (AGEs) and their involvement in liver disease.
Hyogo H; Yamagishi S
Curr Pharm Des; 2008; 14(10):969-72. PubMed ID: 18473847
[TBL] [Abstract][Full Text] [Related]
4. Advanced glycation end products (AGEs) and their receptor (RAGE) system in diabetic retinopathy.
Yamagishi S; Nakamura K; Matsui T
Curr Drug Discov Technol; 2006 Mar; 3(1):83-8. PubMed ID: 16712466
[TBL] [Abstract][Full Text] [Related]
5. Role of advanced glycation end products (AGEs) in osteoporosis in diabetes.
Yamagishi S
Curr Drug Targets; 2011 Dec; 12(14):2096-102. PubMed ID: 22023404
[TBL] [Abstract][Full Text] [Related]
6. Food-derived advanced glycation end products (AGEs): a novel therapeutic target for various disorders.
Yamagishi S; Ueda S; Okuda S
Curr Pharm Des; 2007; 13(27):2832-6. PubMed ID: 17897026
[TBL] [Abstract][Full Text] [Related]
7. DNA-aptamers raised against AGEs as a blocker of various aging-related disorders.
Yamagishi S; Taguchi K; Fukami K
Glycoconj J; 2016 Aug; 33(4):683-90. PubMed ID: 27338620
[TBL] [Abstract][Full Text] [Related]
8. The receptor for advanced glycation end-products has a central role in mediating the effects of advanced glycation end-products on the development of vascular disease in diabetes mellitus.
Hori O; Yan SD; Ogawa S; Kuwabara K; Matsumoto M; Stern D; Schmidt AM
Nephrol Dial Transplant; 1996; 11 Suppl 5():13-6. PubMed ID: 9044300
[TBL] [Abstract][Full Text] [Related]
9. Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer's disease.
Takeuchi M; Yamagishi S
Curr Pharm Des; 2008; 14(10):973-8. PubMed ID: 18473848
[TBL] [Abstract][Full Text] [Related]
10. Advanced Glycation End Products and Diabetes Mellitus: Mechanisms and Perspectives.
Khalid M; Petroianu G; Adem A
Biomolecules; 2022 Apr; 12(4):. PubMed ID: 35454131
[TBL] [Abstract][Full Text] [Related]
11. RAGE influences obesity in mice. Effects of the presence of RAGE on weight gain, AGE accumulation, and insulin levels in mice on a high fat diet.
Leuner B; Max M; Thamm K; Kausler C; Yakobus Y; Bierhaus A; Sel S; Hofmann B; Silber RE; Simm A; Nass N
Z Gerontol Geriatr; 2012 Feb; 45(2):102-8. PubMed ID: 22350391
[TBL] [Abstract][Full Text] [Related]
12. Role of advanced glycation end products (AGEs) and oxidative stress in diabetic retinopathy.
Yamagishi S; Ueda S; Matsui T; Nakamura K; Okuda S
Curr Pharm Des; 2008; 14(10):962-8. PubMed ID: 18473846
[TBL] [Abstract][Full Text] [Related]
13. Receptor for advanced glycation end products (RAGE): a novel therapeutic target for diabetic vascular complication.
Yamagishi S; Nakamura K; Matsui T; Noda Y; Imaizumi T
Curr Pharm Des; 2008; 14(5):487-95. PubMed ID: 18289075
[TBL] [Abstract][Full Text] [Related]
14. Involvement of the toxic AGEs (TAGE)-RAGE system in the pathogenesis of diabetic vascular complications: a novel therapeutic strategy.
Takeuchi M; Takino J; Yamagishi S
Curr Drug Targets; 2010 Nov; 11(11):1468-82. PubMed ID: 20583971
[TBL] [Abstract][Full Text] [Related]
15. Advanced Glycation End Products: A Molecular Target for Vascular Complications in Diabetes.
Yamagishi S; Nakamura N; Suematsu M; Kaseda K; Matsui T
Mol Med; 2015 Oct; 21 Suppl 1(Suppl 1):S32-40. PubMed ID: 26605646
[TBL] [Abstract][Full Text] [Related]
16. Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications.
Yamagishi S; Nakamura K; Matsui T; Ueda S; Fukami K; Okuda S
Expert Opin Investig Drugs; 2008 Jul; 17(7):983-96. PubMed ID: 18549336
[TBL] [Abstract][Full Text] [Related]
17. Advanced glycation endproducts and diabetes. Beyond vascular complications.
Puddu A; Viviani GL
Endocr Metab Immune Disord Drug Targets; 2011 Jun; 11(2):132-40. PubMed ID: 21476962
[TBL] [Abstract][Full Text] [Related]
18. Advanced glycation end product ligands for the receptor for advanced glycation end products: biochemical characterization and formation kinetics.
Valencia JV; Weldon SC; Quinn D; Kiers GH; DeGroot J; TeKoppele JM; Hughes TE
Anal Biochem; 2004 Jan; 324(1):68-78. PubMed ID: 14654047
[TBL] [Abstract][Full Text] [Related]
19. Reduction of advanced-glycation end products levels and inhibition of RAGE signaling decreases rat vascular calcification induced by diabetes.
Brodeur MR; Bouvet C; Bouchard S; Moreau S; Leblond J; Deblois D; Moreau P
PLoS One; 2014; 9(1):e85922. PubMed ID: 24465790
[TBL] [Abstract][Full Text] [Related]
20. The role of AGEs in cardiovascular disease.
Jandeleit-Dahm K; Cooper ME
Curr Pharm Des; 2008; 14(10):979-86. PubMed ID: 18473849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
